When the drugs don't work: The potential of glutamatergic antipsychotics in schizophrenia

British Journal of Psychiatry

Volumn 202, Issue 2, 2013, Pages 91-93

  Papanastasiou, Evangelos ^a   Stone, James M ^b   Shergill, Sukhi ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ACETYLCYSTEINE; CALCIUM ION; CYCLOSERINE; DEXTRO ALANINE; DEXTRO SERINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE; GLYCINE RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; KETAMINE; LIGAND; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PARTIAL AGONIST; PHENCYCLIDINE; PLACEBO; POMAGLUMETAD METHIONIL; SARCOSINE; SEROTONIN 2C ANTAGONIST; SEROTONIN 6 ANTAGONIST;

ABSENCE OF SIDE EFFECTS; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG BINDING SITE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TREATMENT FAILURE; EXCITOTOXICITY; HIPPOCAMPUS; HUMAN; INTERNEURON; NEUROTOXICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; SCHIZOPHRENIA; SYNAPSE;

ALLOSTERIC REGULATION; ANTIPSYCHOTIC AGENTS; EXCITATORY AMINO ACID AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, DOPAMINE D2; RECEPTORS, GLUTAMATE; SCHIZOPHRENIA; TREATMENT FAILURE;

EID: 84873455187     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.112.110999     Document Type: Article

References (15)

1. Haro JM, Novick D, Bertsch J, Karagianis J, Dossenbach M, Jones PB. Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study. Br J Psychiatry 2011;199: 194-201.
2. Stone JM. Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia? Ther Adv Psychopharmacol 2011;1: 5-18.
3. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51: 199-214.
4. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995;6: 869-72.
5. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52: 998-1007.
6. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17: 2921-7.
7. Ayalew M, Le-Niculescu H, Levey DF, Jain N, Changala B, Patel SD, et al. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry 2012;17: 887-905.
8. Pilowsky LS, Bressan RA, Stone JM, Erlandsson K, Mulligan RS, Krystal JH, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 2006;11: 118-9.
9. Law AJ, Deakin JF. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 2001;12: 2971-4.
10. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophr Bull 2011;July 11 (Epub ahead of print).
11. Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology 2012;37: 2515-21.
12. Ellenbroek BA. Psychopharmacological treatment of schizophrenia: what do we have, and what could we get? Neuropharmacology 2012;62: 1371-80.
13. Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 2011;25: 859-85.
14. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13: 1102-7.
15. Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 2011;31: 349-55.